27 studies found for:    weill AND intravenous (iv) therapy | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Bevacizumab and Carboplatin
2 Recruiting A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Conditions: Alloimmune Thrombocytopenia;   Fetal Alloimmune Thrombocytopenia
Intervention: Drug: IVIG (Intravenous Immunoglobulin)
3 Recruiting Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery
Condition: Video-assisted Thoracic Surgery
Interventions: Drug: IV Acetaminophen;   Drug: Saline Placebo
4 Recruiting BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
Conditions: Metastatic Cancer;   Cancer;   Solid Tumor
Interventions: Drug: BP31510 monotherapy;   Drug: BP31510 in combination with chemotherapy
5 Recruiting Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme (GBM);   ANAPLASTIC ASTROCYTOMA (AOA)
Intervention: Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab
6 Recruiting Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
Conditions: Glioblastoma Multiforme;   Fibrillary Astrocytoma of Brain;   Glioma of Brainstem;   Anaplastic Astrocytoma;   Pilomyxoid Astrocytoma;   Mixed Oligodendroglioma-Astrocytoma;   Brain Stem Glioma;   Diffuse Intrinsic Pontine Glioma;   High Grade Glioma
Intervention: Drug: SIACI of Erbitux (200 m/m2) and Bevacizumab(15 mg/kg)
7 Recruiting Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
8 Recruiting Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: PD 0332991;   Drug: bortezomib
9 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
10 Recruiting Lenalidomide, Rituximab, and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: idelalisib;   Drug: lenalidomide
11 Recruiting Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Conditions: Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Chronic Myelomonocytic Leukemia;   Cytopenia
Intervention: Drug: rigosertib sodium
12 Recruiting Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Biliary Stricture;   Biliary Obstruction;   Bile Duct Cancer
Intervention: Procedure: Photodynamic Therapy
13 Not yet recruiting Safety Study of Gene Transfer Vector to Treat alpha1-antitrypsin Deficiency
Condition: alpha1-antitrypsin Deficiency
Intervention: Genetic: AAVrh.10halpha1AT
14 Recruiting Study of Procoagulation Markers in Stroke Patients
Conditions: Stroke;   Hyperglycemia;   Procoagulation Markers
Intervention: Other: Glycemic Control
15 Recruiting The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Condition: Delirium
Interventions: Drug: Ketamine (0.5 mg/kg);   Drug: Normal Saline (placebo);   Drug: Ketamine (1 mg/kg)
16 Recruiting Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: pracinostat;   Drug: Placebo;   Drug: Azacitidine
17 Recruiting Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Condition: KRAS Mutant Metastatic Colorectal Cancer
Interventions: Biological: REOLYSIN®;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Fluorouracil (5-FU);   Drug: Bevacizumab
18 Recruiting Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Conditions: Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission;   Acute Lymphoblastic Leukemia (ALL) in 1st or Subsequent Remission;   Chronic Myelogenous Leukemia (CML);   Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission;   Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma (MM);   Myelodysplastic Syndrome (MDS);   Myeloproliferative Disorder (MPD)
Interventions: Drug: POL6326;   Procedure: Leukapheresis;   Procedure: PBSC Transplant
19 Recruiting Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63)
20 Recruiting Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib;   Drug: Pralatrexate;   Drug: Gemcitabine;   Drug: Romidepsin

Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results
Indicates status has not been verified in more than two years